摘要
目的观察血塞通注射液联合地尔硫治疗慢性肺源性心脏病的临床疗效。方法选取2014年1月—2015年1月扬中市人民医院呼吸内科收治的慢性肺源性心脏病患者86例,随机分为对照组和治疗组,每组各43例。对照组在基础治疗上口服盐酸地尔硫片,1片/次,3次/d。治疗组在对照组的治疗基础上静脉滴注血塞通注射液,0.2 g加入5%葡萄糖注射液250 m L中,1次/d。两组均连续治疗14 d。观察两组的临床疗效,同时比较两组治疗前后血浆黏度、红细胞压积、二氧化碳分压(Pa CO2)、氧分压(Pa O2)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为72.09%、88.37%,两组总有效率比较差异具有统计学意义(P<0.05)。治疗后,两组血浆黏度、红细胞压积、Pa CO2均显著降低,Pa O2显著升高,同组治疗前后差异有统计学意义(P<0.05);且治疗后治疗组这些观察指标的改善程度优于对照组,两组比较差异具有统计学意义(P<0.05)。结论血塞通注射液联合地尔硫治疗慢性肺源性心脏病临床疗效确切,可改善患者血液流变学和血气分析相关指标,具有一定的临床推广应用价值。
Objective To observe the clinical effect of Xuesaitong Injection combined with diltiazem in treatment of chronic pulmonary heart disease.Methods Patients （86 cases） with chronic pulmonary heart disease in Department of Respiratory of People’s Hospital of Yangzhong City from January 2014 to January 2015 were randomly divided into control and treatment groups, and each group had 43 cases. The patients in the control group werepoadministered with Diltiazem Hydrochloride Tablets on the basis of foundation treatment, 1 tablet/time, three times daily. The patients in the treatment group were ivadministered with Xuesaitong Injection on the basis of the control group, 0.2 g Xuesaitong Injection added into 5% Glucose Injection 250 mL, once daily. The patients in two groups were treated for 14 d. After treatment, the efficacy was evaluated, and the changes of plasma viscosity, erythrocyte deposited, PaCO2, and PaO2in two groups before and after treatment were compared.Results After treatment, the efficacies in the control and treatment groups were 72.09% and 88.37%, respectively, and there were differences between two groups （P〈 0.05）. After treatment, plasma viscosity, erythrocyte deposited, and PaCO2 were significantly decreased, PaO2 was significantly increased, and the difference was statistically significant in the same group （P〈0.05）. These observational indexes in the treatment group were better than those in the control group, with significant difference between two groups （P〈0.05）. Conclusion Xuesaitong Injection combined with diltiazem has clinical curative effect in treatment of chronic pulmonary heart disease, and can improve blood rheology and blood gas analysis related indicators, which has a certain clinical application value.
出处
《现代药物与临床》
CAS
2015年第11期1349-1352,共4页
Drugs & Clinic
